 Life Science Investor Mandates (June 2 - June 8) |
| |
|
Invests in Preclinical and Phase I Oncology and Dermatology Drugs
|
Seeks Small Molecules and Biologics from North America and Europe
|
|
Seeks Huge Markets in Medtech and Diagnostics
|
|
Raises New Fund For Early Stage Biotech and Medtech Deals
|
|
|
 For the first time ever, RESI is taking the Innovation Challenge to MaRS Discovery District in Toronto, Canada on June 23. The competition will feature 30 handpicked early stage innovators from MaRS and across North America.
From a competitive pool of applicants, these entrepreneurs have been selected by LSN's scientific validation team based on their scientific merit and "investor readiness." The 30 companies bring together cutting-edge innovations across healthcare IT, biotech, medical device, and diagnostics...
|
 |
|
As we approach our third RESI event of 2016, LSN prides itself on continuing to foster an environment that allows entrepreneurs to effectively engage with investors, strategic partners and other key stakeholders that have the ability to move the needle in their venture. The value in robust networking/partnering coupled with first-hand insight from veteran investors and industry leaders, for diagnostic entrepreneurs is clear.
Moderated by Tom Miller, Managing Partner, GreyBird Ventures, this session will feature: - Nicola Urbani, Investment Director, Emerillon Capital
- John Steuart, Managing Director, Steuart Ventures
- Kathryn Deuchars, Director, Ontario Personalized Medicine Network, Ontario Genomics
- Jeff Summer, SVP Business Development, Clinical Affairs & Genetics, LifeLabs
|
|
By Nono Hu, Director of Marketing, LSN
 With the third installment of the summer reading series we take a look at the important decision of whether or not one should use a fundraising partner to help them in securing capital. Chapter 3 of The Life Science Executive's Fundraising Manifesto, "Going It Alone or Choosing a Fundraising Partner," tackles this question head-on, describing what companies would be a suitable fit for fundraising partners, providing a breakdown of the different types in the marketplace today, and advising readers on how to go about vetting a potential partner. |  |
We hope you enjoy this chapter. Next week, join us for "Chapter 4: Categories of Life Science Investors."
|
|
|
